Transaction in Own Shares

Summary by AI ^BETAClose X

CVS Group plc has announced the purchase of 30,898 ordinary shares on January 8, 2026, as part of its share buyback program, with prices ranging from 1,298.00 pence to 1,326.00 pence per share, averaging 1,310.61 pence. These shares will be cancelled, reducing the total number of issued ordinary shares to 70,581,631. Since the program's inception, CVS has repurchased 1,159,152 shares at a weighted average price of 1,228.99 pence.

Disclaimer*

CVS Group plc

09 January 2026

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

Transaction in own shares

CVS announces that on 08 January 2026 it purchased the following number of its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the terms of the share buyback programme announced on 24 October 2025 (the "Share Buyback Programme").

Date of purchase:	08/01/2026
Aggregate number of Ordinary Shares purchased:	30,898
Lowest price paid per share (GBp):	1,298.00
Highest price paid per share (GBp):	1,326.00
Volume weighted average price paid per share (GBp):	1,310.61

CVS intends to cancel all of the purchased Ordinary Shares.

Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 70,581,631 Ordinary Shares in issue and holds no Ordinary Shares in treasury.

The total number of voting rights in CVS is therefore 70,581,631 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.

Since the commencement of the Share Buyback Programme, the Company has repurchased 1,159,152 Ordinary Shares in aggregate at a weighted average price of 1,228.99 pence per share.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback Programme.

Individual transactions:

Number of Ordinary Shares purchased	Transaction price (GBp share)	Time of transaction (UK Time)	Transaction reference number	Trading Venue
Number of Ordinary Shares purchased	Transaction price (GBp share)	Time of transaction (UK Time)	Transaction reference number	Trading Venue
66	1322	08/01/2026 08:01:00	1366925565233512	XLON
216	1322	08/01/2026 08:06:18	1366925565234731	XLON
304	1322	08/01/2026 08:06:18	1366925565234744	XLON
1322	1326	08/01/2026 08:12:58	1366925565235644	XLON
625	1326	08/01/2026 08:12:58	1366925565235651	XLON
277	1324	08/01/2026 08:17:17	1366925565236330	XLON
139	1322	08/01/2026 08:29:47	1366925565238411	XLON
99	1320	08/01/2026 08:29:47	1366925565238415	XLON
290	1320	08/01/2026 08:29:47	1366925565238414	XLON
550	1320	08/01/2026 08:31:19	1366925565238691	XLON
962	1318	08/01/2026 08:38:04	1366925565239624	XLON
66	1320	08/01/2026 08:38:09	1366925565239658	XLON
1104	1318	08/01/2026 08:40:03	1366925565239903	XLON
290	1318	08/01/2026 08:40:03	1366925565239905	XLON
20	1318	08/01/2026 08:40:03	1366925565239906	XLON
796	1318	08/01/2026 08:40:03	1366925565239907	XLON
1050	1318	08/01/2026 08:40:44	1366925565240010	XLON
290	1318	08/01/2026 08:40:45	1366925565240011	XLON
805	1318	08/01/2026 08:40:45	1366925565240012	XLON
122	1318	08/01/2026 08:41:08	1366925565240077	XLON
915	1316	08/01/2026 08:49:00	1366925565240863	XLON
327	1316	08/01/2026 08:49:00	1366925565240865	XLON
397	1310	08/01/2026 08:56:44	1366925565241742	XLON
334	1310	08/01/2026 08:56:44	1366925565241745	XLON
425	1310	08/01/2026 09:20:29	1366925565245248	XLON
1	1310	08/01/2026 09:20:29	1366925565245249	XLON
73	1310	08/01/2026 09:20:30	1366925565245256	XLON
66	1310	08/01/2026 09:20:36	1366925565245278	XLON
136	1308	08/01/2026 09:25:52	1366925565245718	XLON
995	1308	08/01/2026 09:25:52	1366925565245721	XLON
974	1306	08/01/2026 09:26:20	1366925565245806	XLON
964	1306	08/01/2026 09:26:20	1366925565245809	XLON
961	1304	08/01/2026 09:27:00	1366925565245903	XLON
103	1304	08/01/2026 09:27:10	1366925565245960	XLON
202	1306	08/01/2026 09:28:58	1366925565246136	XLON
440	1306	08/01/2026 09:28:58	1366925565246137	XLON
116	1308	08/01/2026 09:33:03	1366925565246664	XLON
263	1306	08/01/2026 09:34:18	1366925565246827	XLON
928	1306	08/01/2026 09:34:56	1366925565246848	XLON
914	1308	08/01/2026 09:39:15	1366925565247201	XLON
255	1308	08/01/2026 09:39:15	1366925565247202	XLON
282	1308	08/01/2026 09:39:15	1366925565247203	XLON
213	1306	08/01/2026 09:39:23	1366925565247223	XLON
1	1304	08/01/2026 09:43:25	1366925565247748	XLON
37	1304	08/01/2026 09:43:25	1366925565247749	XLON
1	1304	08/01/2026 09:43:30	1366925565247755	XLON
32	1304	08/01/2026 09:43:30	1366925565247756	XLON
108	1304	08/01/2026 09:43:30	1366925565247757	XLON
11	1304	08/01/2026 09:43:31	1366925565247758	XLON
66	1310	08/01/2026 09:54:04	1366925565248862	XLON
745	1308	08/01/2026 10:22:57	1366925565251594	XLON
507	1306	08/01/2026 10:23:01	1366925565251612	XLON
304	1306	08/01/2026 10:23:06	1366925565251622	XLON
356	1308	08/01/2026 10:28:24	1366925565252068	XLON
103	1308	08/01/2026 10:28:24	1366925565252073	XLON
8	1308	08/01/2026 10:28:24	1366925565252074	XLON
253	1308	08/01/2026 10:30:46	1366925565252215	XLON
138	1306	08/01/2026 10:35:56	1366925565252647	XLON
468	1312	08/01/2026 11:08:50	1366925565254720	XLON
422	1312	08/01/2026 11:08:50	1366925565254721	XLON
456	1310	08/01/2026 11:17:13	1366925565255297	XLON
512	1310	08/01/2026 11:32:38	1366925565256171	XLON
195	1308	08/01/2026 11:32:50	1366925565256183	XLON
140	1306	08/01/2026 11:37:25	1366925565256357	XLON
3	1304	08/01/2026 11:45:29	1366925565256831	XLON
905	1304	08/01/2026 11:45:29	1366925565256832	XLON
905	1302	08/01/2026 11:47:38	1366925565256965	XLON
592	1302	08/01/2026 11:47:38	1366925565256967	XLON
316	1302	08/01/2026 11:47:38	1366925565256968	XLON
905	1300	08/01/2026 11:49:53	1366925565257082	XLON
899	1300	08/01/2026 11:49:53	1366925565257087	XLON
766	1300	08/01/2026 11:55:17	1366925565257496	XLON
98	1300	08/01/2026 11:55:17	1366925565257497	XLON
71	1298	08/01/2026 11:58:17	1366925565257613	XLON
454	1306	08/01/2026 15:26:45	1366925565288010	XLON
444	1306	08/01/2026 15:26:45	1366925565288013	XLON

Contacts

CVS Group plc via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

Peel Hunt LLP (Nominated Adviser & Joint Broker) +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

Camarco (Financial PR) cvsg@camarco.co.uk

Ginny Pulbrook +44 (0)7961 315 138

Letaba Rimell

Tilly Butcher

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END